Tivic Health Systems Business Summary

Tivic Health Systems, Inc. (TIVC) is currently executing a strategic pivot from a consumer-focused bioelectronic device manufacturer to a late-stage immunotherapeutics and health technology firm. Historically reliant on direct-to-consumer (DTC) transaction fees from its FDA-cleared ClearUP sinus relief device, the company is winding down its consumer segment to focus on its high-growth Biologics and Bioelectronic Medicine divisions. Revenue generation is transitioning toward a hybrid model of biopharmaceutical licensing, potential government stockpiling contracts for its lead candidate Entolimod, and third-party service fees through its wholly owned CDMO subsidiary, Velocity Bioworks. In the competitive landscape of medical equipment and specialty therapeutics, Tivic contends with players such as enVVeno Medical (NVNO), Zynex (ZYXI), and Nuwellis (NUWE), positioning itself as a diversified developer that uniquely integrates neural pathway modulation with molecular immunology. The company was co-founded by CEO Jennifer Ernst and John Claude, with Ernst bringing over 20 years of go-to-market experience from Xerox PARC and a former tenure as CEO of Thin Film Electronics’ U.S. subsidiary. The leadership team was significantly bolstered in January 2026 by the appointment of Michael K. Handley as Chief Operating Officer and President of Biopharma; Handley previously served as CEO of Statera Biopharma and has a track record of commercializing 17 drugs and devices. Financial oversight is led by CFO Lisa Wolf, a CPA with 30 years of experience in life sciences and technology, while scientific strategy is directed by Chief Scientific Officer Blake Gurfein. Tivic’s strategic initiatives are supported by a board including Sheryle Bolton and Dean Zikria, and the company recently secured a $50 million equity line from Tumim Stone Capital to fund its transition into a diversified therapeutics powerhouse.